Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. - Wikidata - wikimedia - TriplyDB

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

http://www.wikidata.org/entity/Q34479098

about

Stabilization of high-risk plaques From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications Unmet Needs in LDL-C Lowering: When Statins Won't Do!PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab The relationship between Lp(a) and CVD outcomes: a systematic review Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.The metabolic vascular syndrome - guide to an individualized treatment Familial hypercholesterolemia: Review of diagnosis, screening, and treatment Lipids, blood pressure and kidney update 2015 Bioactive Plant Metabolites in the Management of Non-Communicable Metabolic Diseases: Looking at Opportunities beyond the Horizon Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research PCSK9 inhibition: the way forward in the treatment of dyslipidemia Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials Overview of guidelines for the management of dyslipidemia: EU perspectives Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future Glycaemic Effects of Non-statin Lipid-Lowering Therapies Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders The year in cardiology 2015: prevention New Era of Lipid-Lowering Drugs Overcoming Challenges With Statin Therapy Statin-Associated Muscle Adverse Events: Update for clinicians Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future PCSK9 inhibitors - clinical applications Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia A Comparative Overview of Prescription Omega-3 Fatty Acid Products Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?Lipoprotein(a) in nephrological patients Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes.Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date Leveraging human genetics to guide drug target discovery.Statin intolerance - a question of definition.LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation.

P2860

Q26738584-E6E702A4-6E2E-49C4-A9DC-4187D728E15D Q26741078-E6DC2B00-6BB8-4EFD-B90D-8526ACD4989E Q26741705-C50C77F0-A251-4F14-ADA0-AD43E852811A Q26747776-12FCD2BA-B12D-4AD2-B30D-4BC422CC62A8 Q26749317-919EA1ED-2485-4ECB-BAF8-DB9DF577B9D6 Q26752919-294EABC9-43BB-4527-B8B7-E6C2176460DA Q26752950-4E015D32-16B9-452D-832C-A0E7A1842663 Q26766157-35F4429E-3581-4D78-B9C1-55E2A7142B86 Q26767142-D5291BDE-9A1A-4383-ABD3-535DA1CE13BE Q26770143-86A234B8-D903-439E-A3EF-2C42E23BE7BB Q26771550-B3DEEE93-B992-4355-A2C7-21A88ACA79DD Q26771980-9D5E3B4B-50EE-40F7-A921-3379FC4129D8 Q26777184-93B5132E-4635-42F6-B095-847730AE3D5A Q26782844-0B3F6EC0-91EA-4EF7-A275-D2FC93E8FB6A Q26784482-A852D00C-08DF-46FE-8561-7B104D0CC28F Q26797486-FCA6BEB6-4527-42F6-81FF-467302C03A59 Q28069411-2B60A091-E668-453A-9B23-0252ED86709B Q28070061-84607E00-5E93-4D5E-898C-BA2B0CD3BCB8 Q28070152-8F65155E-45DE-44DD-8579-098B84DCE85C Q28070296-9F444BAF-E565-4E9B-8838-D06F64D244BE Q28072221-44D80639-F842-4692-BB57-4AA34FDD3D5E Q28072298-A66A6E71-7AF9-44AA-A5E3-D7B6B2B33C63 Q28073319-A0FE24B8-2B80-45AD-9A96-C872C8F9FEBC Q28074144-AE7CB533-2EAF-43AD-83AD-562EBC02ECA7 Q28074451-90E6153B-671D-4666-A139-6D329E86CD54 Q28079757-E9E3D002-3F3D-40E1-BAF5-867E2E440131 Q28084156-05DD5363-FE9F-4957-AF65-CD291FE25C1C Q28275648-A08BE407-1A9D-4452-938A-3FD7C16B5B06 Q28972330-D9838DB9-9909-4416-A728-0FC5F8C4ABC3 Q29994487-97E5548B-32A8-4134-AA37-FB52B91E6A56 Q30234302-25E01488-F708-4C60-9B08-846E84B04974 Q30234612-FB43848B-1302-4B9F-9CE5-9F89567C1C17 Q30234825-0E9038D7-A5C5-40D0-B836-0CB42933E504 Q30236043-4E11C843-1DC8-4A4F-AE6A-561CE277964B Q30238996-D2D47DB5-4D80-49CE-B375-3FE488F08BC5 Q30244599-C5232BB1-F5D9-4649-9766-3391CB6C6AE6 Q30245007-E0D58764-6F58-49A2-97E1-966CF5A17E45 Q30245218-9EFCDFE8-7673-4855-A6C2-3D568000681A Q30248925-9A478C81-75EB-44F4-835F-5E4B1C5CA4AF Q30251918-A6526E1A-8A6E-41F7-AB20-83E7FFF271B9

P2860

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

http://www.wikidata.org/entity/Q34479098

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@ast

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@en

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@nl

type

label

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@ast

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@en

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@nl

altLabel

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

@en

prefLabel

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@ast

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@en

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@nl

P1433

Q34479098-EF46F414-5836-4D36-BE95-BA0C50DA5B1D

P1476

Q34479098-935329CB-59B7-4E24-809E-E677A251F622

P2093

Q34479098-03B457C2-9731-4640-BDB2-F60F6745D710

Q34479098-0B3FCE46-7DEB-4B22-962D-F4E54C22DD08

Q34479098-10550781-0FD7-4192-9603-14722F081332

Q34479098-1353D46C-254C-4C80-9426-8548EEF7CD7A

Q34479098-1E883882-E80B-45EF-845C-50D6BFA941B2

Q34479098-2F37C729-AB80-4FF8-8812-BE54115160BC

Q34479098-371B7DE3-D5F1-4311-A191-54F3E736DE65

Q34479098-3EDC98A5-6344-44ED-9E52-0425CB57F41D

Q34479098-4B2C6388-CBD3-4E43-AD25-E0BBE8987F3C

Q34479098-65929C90-B628-45AD-BBF8-8E5F18429604

P304

Q34479098-E40DBF45-5B02-48DA-A626-7A15600A2294

P31

Q34479098-7654EF76-C6BF-4CC4-B39C-F339A6EB0C5A

P356

Q34479098-7F45B909-CA27-4D9D-8415-16C0253CB1BF

P407

Q34479098-98B32FED-5A2F-4C37-9376-E2D2C8460719

P433

Q34479098-F612B1D6-115F-49B4-9745-1AA7AF0E259B

P478

Q34479098-F4FF70A9-092E-4670-90F3-D9D4EE63A75B

P50

Q34479098-18C5DE12-D8DC-4DF7-B2CA-AC358F388961

Q34479098-577BFA7A-00E6-47CB-AD61-497791D5A888

Q34479098-590D7065-E11B-43C1-8967-C7BF4D36B489

P577

Q34479098-F76C6EF1-EF19-40A3-B836-0DFD42CA86E7

P5875

Q34479098-4EE8F2A7-CC04-4D94-85FF-A7708E9DB7D6

P698

Q34479098-07F8EEE1-F2F1-4A02-90FB-4D47265E942D

P921

Q34479098-07CC779D-871A-4E16-BDBE-60F34596830D

P356

P1433

The New England Journal of Medicine

P1476

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

@en

P2093

Amy McCagg

http://www.w3.org/2001/XMLSchema#string

Andrew M Tershakovec

http://www.w3.org/2001/XMLSchema#string

Basil S Lewis

http://www.w3.org/2001/XMLSchema#string

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

Craig Reist

http://www.w3.org/2001/XMLSchema#string

Erin A Bohula

http://www.w3.org/2001/XMLSchema#string

Gaetano M De Ferrari

http://www.w3.org/2001/XMLSchema#string

Harald Darius

http://www.w3.org/2001/XMLSchema#string

IMPROVE-IT Investigators

http://www.w3.org/2001/XMLSchema#string

J Wouter Jukema

http://www.w3.org/2001/XMLSchema#string

P304

2387-2397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1410489

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

Robert P Giugliano

P577

2015-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277782125

http://www.w3.org/2001/XMLSchema#string

P698

26039521

http://www.w3.org/2001/XMLSchema#string

P921